Pharmacokinetics of a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases : analysis of a phase III, multicentre, prospective, open-label study by Melamed, Isaac R. et al.
Contents lists available at ScienceDirect
European Journal of Pharmaceutical Sciences
journal homepage: www.elsevier.com/locate/ejps
Pharmacokinetics of a novel human intravenous immunoglobulin 10% in
patients with primary immunodeficiency diseases: Analysis of a phase III,
multicentre, prospective, open-label study
Isaac R. Melameda,⁎, Michael Borteb, Laurenz Trawnicekc, Ai-Lan Kobayashid,
Roger H. Kobayashie, Alan Knutsenf, Sudhir Guptag, William Smitsh, Anna Pituch-Noworolskai,
Magdalena Strachj, Grazyna Pulkaj, Hans D. Ochsk, James N. Moyl,m
a IMMUNOe Research Center, 6801 S. Yosemite street, Centennial, CO 80112, USA
b Klinik für Kinder- und Jugendmedizin, Klinikum St. Georg gGmbH, Leipzig, Germany
cOctapharma Pharmazeutika Produktionsges.m.b.H, Oberlaaer Straße 235, 1100 Vienna, Austria
dMidlands Pediatrics, Papillion, NE 68046, USA
eUCLA School of Medicine, Los Angeles, CA 90095, USA
f Saint Louis University, 1 N Grand Blvd, St Louis, MO 63103, USA
gUniversity of California, C240 Med Sci I, Irvine, CA 92697, USA
h The Allergy and Asthma Center, 7222 Engle Rd, Fort Wayne, IN 46804, USA
iUniversity Children's Hospital, Wielicka 265 St., 30-663 Kraków, Poland
j Jagiellonian University Medical College, Świętej Anny 12, 31-008 Kraków, Poland
k Department of Pediatrics, University of Washington and Seattle Children's Research Institute, Seattle, WA 98195, USA
l Division of Pediatric Allergy/Immunology, John H. Stroger, Jr. Hospital of Cook County, 1969 W. Ogden Ave., Chicago, IL 60612, USA
m Rush University Medical Center, 1653 W. Congress Parkway, Chicago, IL 60612, USA
A R T I C L E I N F O
Keywords:
Intravenous immunoglobulin
IVIG
Panzyga®
Pharmacokinetics
Primary antibody deficiencies
A B S T R A C T
Intravenous immunoglobulin (IVIG) therapy is commonly used to treat patients with primary antibody defi-
ciency. This prospective, open-label, non-randomised, multicentre, phase III trial investigated the pharmacoki-
netics of a new 10% liquid IVIG product (panzyga®; Octapharma) in 51 patients aged 2–75 years with common
variable immunodeficiency (n= 43) or X-linked agammaglobulinaemia (n=8). Patients were treated with IVIG
10% every 3 (n=21) or 4 weeks (n=30) at a dose of 200–800mg/kg for 12months. Total immunoglobulin G
(IgG) and subclass concentrations approximately doubled from pre- to 15min post-infusion. The maximum
concentration of total IgG (mean ± SD) was 21.82 ± 5.83 g/L in patients treated 3-weekly and
17.42 ± 3.34 g/L in patients treated 4-weekly. Median trough IgG concentrations were nearly constant over the
course of the study, remaining between 11.0 and 12.2 g/L for patients on the 3-week schedule and between 8.10
and 8.65 g/L for patients on the 4-week schedule. The median terminal half-life of total IgG was 36.1 (range
18.5–65.9) days, with generally similar values for the IgG subclasses (26.7–38.0 days). Median half-lives for
specific antibodies ranged between 21.3 and 51.2 days for anti-cytomegalovirus, anti-Haemophilus influenzae,
anti-measles, anti-tetanus toxoid, anti-varicella zoster virus antibodies, and anti-Streptococcus pneumoniae sub-
type antibodies. Overall, IVIG 10% demonstrated pharmacokinetic properties similar to those of other com-
mercial IVIG 10% preparations and 3- or 4-weekly administration achieved sufficient concentrations of IgG, IgG
subclasses, and specific antibodies, exceeding the recommended level needed to effectively prevent serious
bacterial infections.
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1. Introduction
Primary immunodeficiency diseases (PID) are a heterogeneous
group of disorders characterised by an inability of the immune system
to mount a sufficient response to invading pathogens (Durandy et al.,
2013; Grimbacher et al., 2016; Picard et al., 2018). Antibody defi-
ciencies requiring IgG replacement therapy, such as agammaglobuli-
naemia and common variable immune deficiency (CVID), are the most
common forms of PID (Bonagura, 2013). Immunoglobulin G (IgG),
isolated from pooled serum collected from multiple (usually several
thousand) donors, is used to treat predominant antibody deficiency. IgG
therapy reduces the frequency and severity of infections and duration of
hospitalisation (Wood, 2012). IgG may be administered by intravenous
or subcutaneous routes. Commercially available intravenous im-
munoglobulin (IVIG) products include older lyophilised formulations,
along with 5% and 10% liquid formulations. Lyophilised formulations
take time to reconstitute, and 5% liquid formulations require higher
volumes of fluid to be administered, which can be critical in patients
with significant cardiac or renal disease, and longer infusion times
(Stein, 2010). In contrast, 10% liquid formulations require smaller
volumes and have shorter infusion times.
The half-life of IgG is relatively long for a plasma protein and the
pharmacokinetics are concentration-dependent (Roopenian and
Akilesh, 2007). It is important to establish the pharmacokinetic prop-
erties of each individual IVIG formulation as pharmacokinetic differ-
ences among various IVIG and subcutaneous immunoglobulin (SCIG)
preparations may be important in deciding which is most appropriate
for an individual patient (Bonagura, 2013). Pharmacokinetic data are
also important to ensure that adequate concentrations of total IgG, IgG
subclasses and IgG antibodies specific to common pathogens as well as
adequate trough concentrations are achieved with dosing schedules of a
particular preparation.
A new high-yield, high-purity, glycine-stabilised human intravenous
immunoglobulin at a concentration of 100mg IgG/mL (10%) solution
has been developed by Octapharma AG (panzyga® 10%; Lachen,
Switzerland). Its manufacture involves various precipitation and chro-
matography processes for harvesting and purifying IgG, as well as two
dedicated steps for pathogen safeguarding. IVIG 10% is manufactured
from a large pool of at least 3500 donations of human fresh-frozen
plasma, ensuring that it contains a diverse range of antibodies directed
against pathogens and foreign antigens. The objective of this report is to
present the pharmacokinetic findings from the NGAM-01 study, which
assessed the efficacy, safety, pharmacokinetics and quality of life out-
comes with IVIG 10% therapy in patients with predominant antibody
deficiency (Borte et al., 2017).
2. Materials and methods
2.1. Study design
All 51 patients with predominant antibody deficiency who partici-
pated in the prospective, open-label, non-controlled, non-randomised
phase III study (ClinicalTrials.gov record NCT01012323) of human
IVIG 10% underwent evaluation of serum IgG pharmacokinetic para-
meters.
2.2. Inclusion and exclusion criteria
Full inclusion and exclusion criteria are described in the primary
study publication (Borte et al., 2017). Briefly, patients (aged ≥2 years
and ≤75 years) were included if they had a confirmed diagnosis of
CVID or X-linked agammaglobulinaemia (XLA) and had previously been
treated with a commercial IVIG preparation every 3 or 4 weeks for at
least 6 infusions at a constant dose between 200 and 800mg/kg, with
documented IgG trough serum levels of ≥5.5 g/L during the two pre-
vious infusions prior to study enrolment.
Patients with severe liver impairment (alanine aminotransferase>
3× upper limit of normal), abnormal renal function
(creatinine>120 μmol/L), congestive heart failure (New York Heart
Association class III or IV), non-controlled arterial hypertension (sys-
tolic BP>160mmHg or diastolic BP>90mmHg) or those positive
for human immunodeficiency virus, hepatitis C virus, or hepatitis B
virus were excluded from the study, as were pregnant or breastfeeding
women.
2.3. Treatment
Full treatment details have been presented in the primary study
publication (Borte et al., 2017). IVIG 10% at a dose of 200–800mg/kg
was infused every 3 or 4 weeks (based on patients' previous IVIG dosing
schedule) for 12months, unless medical conditions or other circum-
stances resulted in a patient's withdrawal from the study. Patients re-
ceived either 17 or 13 IVIG 10% infusions, depending on whether their
regular treatment interval was 3 or 4 weeks, respectively. To insure
precise infusion rates, an infusion pump was used, starting at a rate of
0.01mL/kg/min (60mg/kg/h) for the first 30min; if tolerated, rates
were increased every 30min to a maximum infusion rate of 0.08mL/
kg/min (480mg/kg/h).
2.4. Pharmacokinetic assessments and statistical analysis
Blood samples were drawn immediately before each infusion for the
determination of trough serum IgG concentrations. Additional blood
samples for analysis of trough antigen-specific IgG antibodies to cyto-
megalovirus (CMV), H. influenzae, measles, tetanus, varicella zoster
virus (VZV), and 7 S. pneumoniae subtypes (types 4, 6B, 9V, 14, 18C,
19F, 23F) were taken before the first infusion and at 3 to 4 weeks after
the last infusion depending on the patient's dosing scheme.
Pharmacokinetic assessments were carried out after the 7th infusion
(4-week schedule) or after the 9th infusion (3-week schedule). For
analysis of serum concentrations of total IgG and IgG subclasses (IgG1,
IgG2, IgG3 and IgG4) over the course of the treatment interval, blood
samples were drawn prior to the infusion, and then at 15 ± 5min,
60 ± 10min, 24 ± 1 h, 72 ± 6 h, 7 days± 6 h, 14 ± 3 days and
21 ± 3 days (for patients on the 3-week infusion schedule) or
28 ± 3 days (for patients on the 4-week infusion schedule) after the
end of the 9th or 7th infusion, respectively.
The following pharmacokinetic parameters were calculated for total
IgG, IgG subclasses and specific antibodies: peak plasma concentration
(Cmax); time from start of administration to peak plasma concentration
(Tmax); trough plasma concentration (Cmin); terminal half-life (t1/2);
area under the serum concentration-time curve from time 0 to the end
of the dosing period (AUC0–tau); elimination rate constant (kel); volume
of distribution (Vd, measured for total IgG and IgG subclasses only).
The specialised software Phoenix® WinNonlin® version 6.3 (Certara
L.P. [Pharsight], St. Louis, MO) was used for the calculation of non-
compartmental pharmacokinetic parameters.
3. Results
3.1. Patient demographics and treatment regimens
In total, 51 patients comprising 13 children (≥2 to< 12 years), 12
adolescents (≥12 to<16 years) and 26 adults (≥16 years) from 11
study centres in the USA and Europe participated in the study. Baseline
demographics and characteristics of the patients are presented in
Table 1. Out of the 51 patients enrolled in the study, 43 patients
(84.3%) were diagnosed with CVID and eight patients (15.7%) were
diagnosed with XLA. A total of 45 patients (88.2%) took prior medi-
cation other than a commercial IVIG before entering the study. Overall,
21 patients received IVIG 10% in a 3-week interval and 30 patients
received treatment in a 4-week schedule.
I.R. Melamed et al. European Journal of Pharmaceutical Sciences 118 (2018) 80–86
81
3.2. Total IgG and IgG subclass pharmacokinetics
Mean serum concentrations of IgG and IgG subclasses prior to and
15min post IVIG 10% infusion are reported in Table 2. In general,
median values demonstrated an approximate 2-fold increase from pre-
to post-infusion. Median total IgG concentrations increased from a pre-
infusion level of 9.3 g/L to 17.6 g/L at 15min post-infusion.
Mean serum concentrations of total IgG and IgG subclasses followed
a similar pattern after an IVIG 10% infusion, with a steeper decline
from their peaks just after the end of infusion followed by a slower
terminal elimination phase (Fig. 1). This profile was observed both for
the 3-weekly and 4-weekly treatment schedules. As expected, IgG1 and
IgG2 were present in much higher concentrations than the IgG3 and
IgG4 subclasses (Fig. 1).
In most IgG and IgG subclass pharmacokinetic parameters, a wide
degree of inter-patient variability was evident. The pharmacokinetic
estimates for the IgG subclasses and total IgG are presented in Table 3.
For total IgG and all four IgG subclasses the median values in patients
on 3-week schedule were about 20% to 30% higher than in patients on
4-week schedule.
Over the course of the study, median trough IgG levels varied be-
tween 11.0 and 12.2 g/L for patients on the 3-week IVIG 10% schedule
and between 8.1 and 8.7 g/L for patients on the 4-week schedule. The
lowest trough plasma concentration of IgG calculated for both treat-
ment schedules was above 6.8 g/L: the median (minimum–maximum)
was 13.2 (7.7–20.4) g/L for 3-weekly administration and 9.0 (6.8–20.6)
g/L for 4-weekly administration. A greater proportion of patients re-
ceived a dose of IVIG 10% > 0.5 g/kg on the 3-week schedule
(52.38%; mean dose of 520mg/kg/infusion or 173mg/kg/week) than
on the 4-week schedule (36.67%; mean dose of 453mg/kg/infusion or
113mg/kg/week).
The estimated median terminal half-life of total IgG for both 3- and
4-week groups was 36.1 days (range 18.5–65.91), with similar values
reported for IgG 1, IgG2 and IgG4 (median 30.7 to 38.0 days), and a
lower value for IgG3 (26.7 days). For IgG3 and IgG4, there was a
greater degree of variability in half-life among patients than for IgG1
and IgG2 (Table 3).
3.3. Specific antibodies
Pharmacokinetic data for antibodies against CMV, H. influenzae,
measles, tetanus, VZV, and 7 S. pneumoniae subtypes are listed in
Table 4. The data show high levels of a broad range of specific anti-
bodies directed against these pathogens. There was no trend favourable
to the 3-week or 4-week treatment schedule. Median half-lives for
specific antibodies ranged between 21.3 and 51.2 days for anti-CMV,
anti-H. influenzae, anti-measles, anti-tetanus toxoid, and anti-VZV an-
tibodies, and between 31.1 and 35.9 days for anti-S. pneumoniae sub-
type antibodies.
Particularly marked increases in antibody median trough levels
from first infusion to treatment end were noticed in both treatment
schedules for anti-measles (824.0 to 1300.0 mIU/mL for the 3-week
schedule and 680.5 to 1051.0 mIU/mL for the 4-week schedule), anti-H.
influenzae (1.64 to 2.36 μg/mL for the 3-week schedule and 1.30 to
1.68 μg/mL for the 4-week schedule) and anti-S. pneumoniae serotype
6B (1.94 to 2.56 μg/mL for the 3-week schedule and 1.39 to 1.55 μg/mL
for the 4-week schedule). All these trough levels are considered as being
protective. Other S. pneumoniae serotypes showed a slight increase of
antibody trough concentrations over time in at least one of the two
treatment schedules. Trough antibody concentrations remained stable
over the course of the study for anti-CMV, and showed a slight decrease
for anti-tetanus toxoid (3-week schedule) and anti-VZV antibodies (4-
week schedule).
3.4. Safety
Patients in the 4-weekly group had a higher incidence of serious AEs
(SAEs; 13 vs. 5%). In contrast, more patients in the 3-weekly treatment
group had severe AEs than patients in the 4-weekly group (24 vs. 7%).
Only two patients required premedication (3.9% of patients) for three
infusions (0.4% of infusions). Study medication-related (possible or
probable) treatment-emergent AEs occurred during 38 infusions (5.1%
of infusions: 2.7% in children, 2.2% in adolescent, and 7.8% in adult
infusions); headache was the most abundant and noted in 22 infusions
(3.0%).
The low rate of other infections (3.7 per patient/year) confirms that
the dosing and corresponding trough levels observed in this study were
adequate. The average dose administered was 485mg/kg body weight
per infusion or 138mg/kg/week, being in line with doses re-
commended in the core summary of product characteristics. For further
details on the safety profile please refer to the main panzyga® pub-
lication of Borte et al., 2017.
4. Discussion
This study characterises the pharmacokinetics of total IgG, IgG
subclasses and specific antibodies after administration of IVIG 10% in
patients with predominant antibody deficiency. Pharmacokinetic as-
sessments were conducted after patients had received IVIG 10% for
24 weeks (seven infusions in the 4-week schedule or nine infusions in
the 3-week schedule), at which time any carryover from previous IgG
therapy would have been eliminated.
As expected, administration of IVIG typically produces an im-
mediate rise in serum IgG concentration followed by a rapid fall as IgG
exits the vasculature into the extracellular space and the lymphatics,
finally entering a slower period of decline associated with catabolism as
IgG in these fluid spaces equilibrates and constantly enters and exits the
circulation (Bonilla, 2008). In the context of IVIG replacement therapy,
key parameters are IgG trough levels (immediate pre-infusion) and the
elimination half-life to describe the expected rate of disappearance of
replacement IgG (Bonilla, 2008).
Patients in this study received IVIG 10% at doses between 200 and
800mg/kg of body weight, in either a 3- or 4-week schedule, to remain
consistent with their IVIG therapy before entering the study. Serum
Table 1
Baseline characteristics and demographics.
Characteristic N=51
Gender, n (%)
Male 33 (64.7)
Female 18 (35.3)
Mean ± SD age, years 26.8 ± 19.3
Age class, n (%)
≥2 to< 12 years 13 (25.5)
≥12 to< 16 years 12 (23.5)
≥16 to ≤75 years 26 (51.0)
Disease type, n (%)
CVID 43 (84.3)
XLA 8 (15.7)
Ethnic group, n (%)
Caucasian 43 (84.3)
Hispanic 7 (13.7)
Not reported 1 (2.0)
Mean ± SD BMI, kg/m2 22.5 ± 6.47
Mean ± SD body weight, kg
≥2 to< 12 years 24.3 ± 6.6
≥12 to< 16 years 57.3 ± 10.8
≥16 to ≤75 years 76.5 ± 19.7
BMI, body mass index, CVID, common variable immunodeficiency;
SD, standard deviation; XLA, X-linked agammaglobulinaemia.
1 One profile showed a t1/2 of 131.7 days, which was treated as an outlier/artefact and
excluded from analyses.
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total IgG trough (pre-infusion) levels were nearly constant for both
treatment groups over the course of the study (median values prior to
the first infusion was 11.9 g/L, at follow-up 12.2 g/L [3-week group]
and median values prior to infusion one: 8.1 g/L, at follow-up: 8.7 g/L
[4-week group]) and remained above the recommended trough level of
5–6 g/L. It is worth noting that there is evidence to suggest that the
incidence of infection decreases as IgG trough levels increase, up to a
maximum of 10 g/L (Gardulf et al., 2006; Orange et al., 2010), in-
dicating that the higher trough concentrations with the 3-weekly dosing
schedule may provide better protection against infection than the 4-
weekly schedule. However, in this study more patients experienced
infections other than serious bacterial infections (SBIs) in the 3-weekly
Table 2
Serum levels of total IgG and IgG subclasses before and after infusion with IVIG 10%.
Sampling time
Pre-infusion 15min post infusion
3-week group (n= 21) 4-week group (n= 30) All patients (n= 51) 3-week group (n=21) 4-week group (n= 30) All patients (n= 51)
Total IgG, g/L 11.8 (7.4, 20.2) 8.2 (6.0, 18.8) 9.3 (6.0, 20.2) 19.8 (9.3, 30.2) 16.1 (12.4, 26.0) 17.6 (9.3, 30.2)
IgG1, g/L 7.0 (4.1, 12.2) 5.3 (3.7, 14.1) 5.7 (3.7, 14.1) 12.6 (5.1, 19.8) 10.2 (7.8, 18.9) 10.8 (5.1, 19.8)
IgG2, g/L 3.9 (2.2, 6.6) 2.9 (2.2, 4.2) 3.3 (2.2, 6.6) 6.8 (3.3, 11.5) 5.7 (4.3, 7.6) 6.1 (3.3, 11.5)
IgG3, g/L 0.3 (0.1, 0.5) 0.2 (0.1, 0.9) 0.2 (0.1, 0.9) 0.6 (0.1, 0.9) 0.5 (0.3, 1.2) 0.5 (0.1, 1.2)
IgG4, g/L 0.4 (0.2, 1.1) 0.2 (0.1, 1.5) 0.3 (0.1, 1.5) 0.8 (0.3, 1.6) 0.6 (0.4, 1.9) 0.6 (0.3, 1.9)
All values are presented as median (minimum, maximum).
Fig. 1. Serum concentrations (mean ± standard deviation) of (A) total IgG and (B–E) IgG subclasses following infusion with IVIG 10% in 30 patients on a 4-week
schedule. The dotted lines indicate the normal physiological serum range of immunoglobulin (normal ranges as described here: http://www.globalrph.com/labs_i.
htm).
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group with higher IgG trough levels than in the 4-weekly group with
lower IgG trough levels. This could have been by chance as the patients
continued with their treatment schedule and dosage they had received
before study participation. It is also possible that patients with a more
compromised immune system and, therefore, at greater risk of devel-
oping such infections, were placed on a 3-weekly schedule (Borte et al.,
2017). On the other hand, both patients with SBIs were in the 4-weekly
group with lower IgG trough levels. All 4 SBIs had onset dates between
24 and 32 days after last infusion when their IgG concentrations were
lower than the average IgG trough levels (mean of 6.7 g/L; range:
6.0–7.9 g/L).
The higher IgG trough levels observed in patients on the 3-week
schedule (range between 11.34 g/L and 12.27 g/L; SD between 2.69
and 3.42) may result in part from the fact that a larger proportion of
patients within this group received IVIG 10% doses > 0.5 g/kg com-
pared with patients on the 4-week schedule who had significantly lower
IgG trough levels (range between 8.48 g/L and 8.98 g/L; SD between
2.16 and 3.02). It has been recommended that for the treatment of
antibody deficiency, IgG concentrations remain above a minimum
trough level of 5 g/L based on data from patients with chronic lung
disease (Roifman et al., 1987), although an optimal trough level to
minimise risk of serious infections has not been definitively established.
Table 3
Pharmacokinetic parameter estimates for total IgG and its subclasses after infusion of IVIG 10% at 3-weekly or 4-weekly intervals.
Note, data from one patient in the 3-week group was excluded because of a very high Tmax value (170 h) so were considered an outlier/artefact.
Parameter, median (min, max) Group Total IgG IgG1 IgG2 IgG3 IgG4
Cmin, g/L 3-week 13.2 (7.7, 20.4) 7.8 (4.4, 12.7) 4.5 (2.2, 6.7) 0.3 (0.1, 0.5) 0.4 (0.2, 1.1)
4-week 9.0 (6.8, 20.6) 5.4 (4.1, 15.2) 3.0 (2.3, 4.4) 0.2 (0.1, 0.8) 0.3 (0.2, 1.6)
Cmax, g/L 3-week 20.5 (14.6, 33.3) 12.7 (8.6, 19.8) 7.3 (3.3, 11.5) 0.6 (0.3, 0.9) 0.8 (0.3, 1.6)
4-week 16.5 (12.7, 26.0) 10.3 (7.9, 18.9) 5.7 (4.4, 7.9) 0.5 (0.3, 1.2) 0.6 (0.4, 1.9)
Tmax, hours 3-week 2.9 (2.1, 25.9) 2.7 (2.1, 25.0) 2.6 (2.1, 74.1) 2.6 (2.1, 26.0) 2.5 (1.6, 25.0)
4-week 2.5 (1.8, 26.3) 2.4 (1.8, 26.3) 2.4 (1.8, 26.3) 2.5 (1.8, 69.0) 2.4 (1.8, 3.3)
t1/2, days 3-week 32.9 (18.5, 76.6) 38.6 (15.5, 72.8) 38.0 (16.2, 65.4) 26.2 (11.5, 59.6) 30.7 (12.5, 68.6)
4-week 37.4 (18.7, 131.7) 35.6 (18.5, 134.7) 38.3 (17.7, 127.7) 27.3 (13.4, 397.9) 30.7 (16.4, 250.3)
AUC0–tau, h·g/L 3-week 7364 (5300, 11,919) 4483 (3117, 7171) 2507 (1290, 4025) 179 (87, 259) 244 (99, 645)
4-week 6980 (5567, 13,778) 4368 (3197, 10,302) 2458 (1879, 3060) 156 (93, 565) 213 (153, 1134)
kel, 1/1000·h 3-week 0.88 (0.4, 1.6) 0.76 (0.4, 1.9) 0.76 (0.4, 1.8) 1.10 (0.5, 2.5) 0.94 (0.4, 2.3)
4-week 0.77 (0.2, 1.6) 0.81 (0.2, 1.6) 0.75 (0.2, 1.6) 1.06 (0.1, 2.2) 0.94 (0.1, 1.8)
Vd, L/kg 3-week 0.09 (0.0, 0.1) 0.08 (0.0, 0.2) 0.09 (0.0, 0.1) 0.09 (0.0, 0.2) 0.09 (0.0, 0.2)
4-week 0.09 (0.0, 0.2) 0.07 (0.0, 0.2) 0.08 (0.0, 0.2) 0.09 (0.0, 0.2) 0.10 (0.0, 0.1)
AUC0–tau, area under the IgG serum concentration-time curve from time 0 to the end of the dosing period; Cmax, peak IgG plasma concentration; Cmin, trough IgG
plasma concentration; kel, elimination rate constant; SD, standard deviation; t1/2, terminal half-life; Tmax, time from start of administration to peak IgG plasma
concentration; Vd, volume of distribution.
Table 4
Derived pharmacokinetic parameters for antigen-specific antibodies after infusion of IVIG 10% (all patients N=51).
Parameter, median (min, max) Baseline (pre-infusion 1) value Cmax, μg/mL Tmax, h AUC0–tau, h× μg/mL Cmin, μg/mL t1/2, days
CMV IgG 30.0
(17.0, 49.0)
44.0a
(31.0, 57.0)
2.4
(1.8, 26.3)
19,811.2b
(13,353.1, 28,314.5)
30.5a
(20.0, 49.0)
51.2
(19.0, 239.8)
H. influenzae IgG 1.6
(0.7, 9.0)
3.8
(1.9, 9.0)
2.5
(1.6, 69.1)
1417.9
(720.0, 6048.0)
2.0
(1.2, 9.0)
34.7
(14.6, 425.8)
Measles IgG 0.7
(0.3, 2.3)
2.3c
(1.3, 5.0)
2.8
(1.8, 169.9)
773.5d
(493.2, 1200.1)
1.0c
(0.3, 1.9)
26.8
(13.7, 317.7)
Tetanus IgG 2.1
(0.6, 5.0)
5.0c
(2.3, 5.0)
2.4
(1.8, 73.8)
1779.6d
(612.7, 3110.1)
2.1c
(0.6, 5.0)
21.3
(7.9, 2205.8)
Varicella zoster IgG 150.0
(89.4, 150.0)
150.0e
(150.0, 150.0)
2.3
(0.3, 3.8)
75,600.0f
(39,977.7, 100,800.0)
150.0e
(29.6, 150.0)
24.9
(9.3, 3386.4)
Serotype 4 0.9
(0.2, 4.6)
2.0
(0.8, 7.0)
2.6
(1.8, 27.4)
687.0
(360.3, 2565.3)
0.9
(0.5, 4.8)
33.4
(16.8, 185.1)
Serotype 6B 1.6
(0.7, 8.3)
3.7
(2.0, 10.7)
2.5
(1.8, 69.1)
1386.5
(721.0, 5408.7)
1.9
(1.0, 8.0)
33.4
(17.7, 213.4)
Serotype 9V 1.6
(0.5, 4.3)
3.7
(1.9, 8.7)
2.6
(1.6, 27.0)
1394.9
(704.8, 2925.5)
1.9
(1.0, 5.1)
34.2
(14.5, 103.3)
Serotype 14 5.9
(2.1, 26.3)
14.4
(6.4, 40.1)
2.6
(1.6, 74.1)
5619.7
(2247.2, 17,017.5)
8.6
(3.2, 31.6)
35.9
(20.2, 161.8)
Serotype 18C 1.7
(0.7, 15.3)
4.3
(1.8, 23.0)
2.5
(1.6, 74.1)
1625.1
(644.2, 5825.2)
2.2
(0.9, 11.0)
34.0
(15.2, 92.3)
Serotype 19F 4.6
(2.4, 18.4)
11.9
(5.7, 32.5)
2.5
(1.8, 27.0)
4319.1
(2183.9, 11,719.1)
5.6
(2.9, 16.0)
32.7
(13.4, 195.0)
Serotype 23F 1.6
(0.5, 8.1)
4.1
(1.8, 8.3)
2.6
(1.6, 27.4)
1503.8
(652.5, 3993.4)
2.1
(0.8, 5.5)
31.1
(16.7, 90.8)
AUC0–tau, area under the IgG serum concentration-time curve from time 0 to the end of the dosing period; Cmax, peak IgG plasma concentration; Cmin, trough IgG
plasma concentration; CMV, cytomegalovirus; IgG, Immunoglobulin G; t1/2, terminal half-life; Tmax, time from administration to peak IgG plasma concentration.
Serotype (4-23F) refers to anti-S. pneumoniae antibodies.
a U.
b h×U.
c IU/mL.
d h× IU/mL.
e U/mL.
f h×U/mL.
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A more realistic determination of an acceptable trough level may be the
patient's baseline IgG level (before being started on IVIG) and ulti-
mately should be determined by clinical outcomes for individual pa-
tients (Bonagura, 2013; Matucci et al., 2015). The mean trough plasma
concentration values after 24 weeks of therapy with IVIG 10% were
well above this threshold for both the 3-week and 4-week infusion in-
tervals and were comparable to those reported for other IVIG products
(Schroeder Jr and Dougherty, 2012; Wasserman, 2014).
The terminal half-lives of IgG and IgG subclasses in the present
study were comparable to those reported in a number of clinical trial of
10% liquid IVIG products in antibody deficient patients (Bjorkander
et al., 2006; Church et al., 2006; European Medicines Agency, 2010;
Wasserman et al., 2009; Ballow et al., 2003; Berger et al., 2010; Bleasel
et al., 2012; Wasserman, 2014; Wasserman et al., 2012). Similar to
what has previously been reported in the literature for IVIG prepara-
tions, there was a wide range in the terminal half-life for IgG (18.5 to
65.9 days) in the present study. This may in part relate to inherent
difficulties in studying IVIG in immunodeficient patients, including a
potential confounding effect of endogenous immunoglobulin produc-
tion and the concentration-dependent nature of IgG catabolism, as well
as the ethical prohibition of withholding IVIG to permit more accurate
estimation of IgG half-life through serial measurements of IgG con-
centrations over several half-life intervals (Bonilla, 2008; Wasserman
et al., 2009). The wide variability in rates of decay of replacement IgG
makes comparisons between different regimens and different IVIG
preparations difficult (Bonilla, 2008).
In the present study, the pharmacokinetic profiles and half-lives of
the antigen-specific IgG antibodies mirrored those of total IgG and IgG
subclasses. The median half-lives of anti-H. influenzae, anti-tetanus
toxoid, anti-S. pneumoniae, anti-measles and anti-CMV antibodies were
in the range of 21.3 to 51.2 days and similar to published values (Berger
et al., 2010; Wasserman et al., 2009; Wasserman et al., 2012). Trough
levels of specific antibodies were stable or increased across the course
of the study, a trend similar to that reported by Nobre et al. (2014). At
present, specific antibody concentrations required for protection from
infection have not been fully defined and the lack of any standardised
tests to estimate specific antibody concentrations makes comparisons of
parameters such as antibody trough levels difficult, and limits the op-
portunity for meaningful information regarding appropriate IVIG doses
to prevent infections (Schroeder Jr and Dougherty, 2012).
While intravenous infusion is the most common method of admin-
istering replacement IgG therapy, subcutaneous immunoglobulin
(SCIG) formulations have also been investigated in the treatment of PID
to address some of the limitations of intravenous therapy, such as sys-
temic side effects, a “wear-off” effect towards the end infusion periods
(Rojavin et al., 2016), and the need for a healthcare professional to
perform the infusions. Currently, 11 IVIG products (two of which are
also approved for subcutaneous injection) and three SCIG products are
approved for use in the US by the Food and Drug Administration (FDA,
2008). Differences in the pharmacokinetics of IVIG and SCIG may be
important in deciding which mode is appropriate for an individual
patient (Bonagura, 2013). IVIG achieves higher peak levels of IgG,
while SCIG achieves higher trough levels, probably due to the increased
frequency of infusion, usually weekly (Bonagura, 2013; Ochs et al.,
2006; Wasserman et al., 2010). A number of studies have implied, in
line with the controversial dose adjustment required by the FDA, that
the amount of subcutaneously administered human immunoglobulin
has to be 1.4 to 1.5 times that of intravenously administered prepara-
tions to maintain pharmacokinetic equivalence (based on AUC) (Berger
et al., 2011; Ochs et al., 2006; Wasserman et al., 2010; Wasserman
et al., 2011a; Wasserman et al., 2011b). However, there are also pub-
lished studies demonstrating that the same dose, or even a lower dose of
SCIG, may be equally effective (Gardulf et al., 2006; Jolles et al., 2011).
A principal limitation of subcutaneous administration of human im-
munoglobulin is the relatively small volume of fluid that can be ad-
ministered by this route (100mL per infusion of 20% SCIG or 20 g vs.
1000mL or 100 g IVIG in an adult), which necessitates more frequent
infusions than IVIG (about once per week vs. every 3 or 4 weeks),
higher concentrations of the Ig preparation (16% to 20% vs. 5% to
12%) and potentially necessitates multiple infusion sites (Garcia-Lloret
et al., 2008). The development of an SCIG product for use in conjunc-
tion with recombinant human hyaluronidase has attempted to address
some of these issues (Wasserman et al., 2016).
A distinguishing feature of the NGAM-01 study design was that all
patients enrolled in the efficacy trial were included in the pharmaco-
kinetic analysis, which is in contrast to many other published studies of
IVIG in which only a subset of the efficacy study population was in-
cluded (Berger et al., 2010; European Medicines Agency, 2010;
Wasserman, 2014; Wasserman et al., 2009; Wasserman et al., 2012). In
addition to the relatively large number of patients included in this
analysis, the strengths of the current study is reflected by the recruit-
ment of patients from both the USA and Europe and the wide age range
(≥2 to ≤75 years) of patients, half of which were children or adoles-
cents. This design ensures the results are applicable to a broad patient
population.
5. Conclusion
Pharmacokinetic data from this prospective, open-label, non-con-
trolled, non-randomised, phase III study demonstrate that IVIG 10%
(panzyga®), when administered at a dose of 200–800mg/kg as an in-
fusion every 3 or 4 weeks to patients with predominant antibody defi-
ciency, achieves adequate concentrations of total IgG, IgG subclasses,
and IgG antibodies to specific common pathogens. Trough levels of total
IgG remained well above the widely accepted threshold of 5–6 g/L. The
terminal half-life of total IgG and IgG subclasses were similar to those
reported for other commercially available IVIG products. The data also
support the more frequent 3-weekly over the 4-weekly administration
as patients given infusions every 3 weeks, while receiving on average a
53% higher weekly dose, showed trough plasma concentrations of IgG
that were 34–37% higher when compared to those receiving 4-weekly
infusions.
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